Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2025 16:05 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
August 26, 2025 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

WALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
August 05, 2025 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary...
July 10, 2025 16:01 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
July 08, 2025 21:36 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
July 08, 2025 16:26 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
July 07, 2025 07:06 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to...
June 11, 2025 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year,...
May 29, 2025 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
May 06, 2025 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Reports First Quarter 2025 Financial Results

Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST...